Rakuten Medical is a biopharmaceutical company developing Akalux, a photoimmunotherapy drug that kills cancer cells by activating a light-sensitive antibody conjugate injected into the tumor site. The approach destroys tumor cells while sparing surrounding healthy tissue, approved in Japan for head and neck cancer.
acquisitions n=0
No cited completed company acquisition recorded.
traction n=0
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
valuations n=0
No cited valuation with an explicit basis is recorded.
revenue multiples n=0
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
Cloudflare, WordPress, Max Mega Menu 3.9.2.1, Yoast SEO 27.5, reCAPTCHA, Google Analytics, Google Tag Manager, SiteOrigin Widgets Bundle 1.72.0, jQuery Migrate 3.4.1, DoubleClick Floodlight, Cloudflare Bot Management, CookieYes 3.4.2